Checkpoint Therapeutics, Inc.
CKPTDelisted May 30, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001651407
Checkpoint Therapeutics, Inc. was delisted on May 30, 2025; its insiders filed their last Form 4 on Jun 3, 2025; 84 institutions reported holding it in 13F filings for Q1 2025, worth $137.7M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 84
- Q1 2025, +16 vs. previous quarter
- 13F value
- $137.7M
- Reported value at the end of Q1 2025
- Superinvestors holding
- 0
- At the end of Q1 2025
Superinvestors holding CKPT, Q1 2025
No superinvestor reported holding CKPT at the end of Q1 2025.
Latest insider trades
Open-market purchases and sales by Checkpoint Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2025 (view filing) | May 29 | 5 daysLate | Fortress Biotech, Inc.10% Owner | SSaleCOMMON STOCK, PAR VALUE $0.0001 | −100.0K | $1.29 | −$129.0K | −1.6%6.12M after | |
| Apr 3, 2025 (view filing) | Apr 2 | 1 day | Oliviero James F IIICEO, President and Director | SSale | −15.1K | $4.04 | −$61.0K | −0.4%3.76M after | |
| Apr 3, 2025 (view filing) | Apr 1 | 2 days | Gray William GarrettChief Financial Officer | SSale | −12.3K | $4.05 | −$49.9K | −0.8%1.45M after | |
| Feb 11, 2025 (view filing) | Feb 7-10 | 4 days | Oliviero James F IIICEO, President and Director | SSale | −19.6K | $3.27 | −$64.0K | −0.5%3.78M after | 2 lots |
| Feb 7, 2025 (view filing) | Feb 6 | 1 day | Gray William GarrettChief Financial Officer | SSale | −74.1K | $3.67 | −$272.0K | −4.8%1.46M after | |
| Dec 20, 2024 (view filing) | Dec 18-19 | 2 days | Oliviero James F IIICEO, President and Director | SSale | −822.4K | $3.74 | −$3.07M | −20.5%3.19M after | 2 lots |
| Dec 20, 2024 (view filing) | Dec 18 | 2 days | Gray William GarrettChief Financial Officer | SSale | −268.4K | $4.01 | −$1.08M | −20.6%1.03M after | |
| Jun 28, 2024 (view filing) | Jun 26 | 2 days | Oliviero James F IIICEO, President and Director | SSale | −24.6K | $2.05 | −$50.5K | −1.2%1.98M after | |
| Jun 28, 2024 (view filing) | Jun 26 | 2 days | Gray William GarrettChief Financial Officer | SSale | −13.0K | $2.06 | −$26.9K | −1.9%672.2K after | |
| Mar 1, 2024 (view filing) | Feb 28 | 2 days | Oliviero James F IIICEO, President and Director | SSale | −5.89K | $2.06 | −$12.1K | −1.7%350.8K after |
Top 10 13F holders, Q1 2025
The largest institutional positions in Checkpoint Therapeutics, Inc. at the end of Q1 2025; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Beryl Capital Management LLC | 6,074,216 | $24.5M | 9.17% | +6,074,216 | New |
| Highbridge Capital Management LLC | 3,831,741 | $15.5M | 0.68% | +3,831,741 | New |
| Toronto Dominion Bank | 3,424,522 | $13.8M | 0.04% | +3,424,522 | New |
| Glazer Capital, LLC | 3,165,000 | $12.8M | 0.59% | +3,165,000 | New |
| Oddo BHF Asset Management SAS | 2,175,000 | $8.79M | 0.36% | +2,175,000 | New |
| Vanguard Group Inc | 2,007,910 | $8.11M | 0.00% | +110,477+5.8% | Added |
| Barclays PLC | 1,294,777 | $5.23M | 0.00% | +1,294,777 | New |
| Gabelli Funds LLC | 1,105,950 | $4.47M | 0.03% | +1,105,950 | New |
| Gabelli & Co Investment Advisers, Inc. | 1,019,750 | $4.12M | 0.62% | +1,019,750 | New |
| Groupe la Francaise | 840,000 | $3.39M | 0.07% | +840,000 | New |